- Home
- BYRN vs RLAY Comparison
BYRN vs RLAY Comparison
Compare BYRN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- RLAY
- Stock Information
- Founded
- BYRN 2005
- RLAY 2015
- Country
- BYRN United States
- RLAY United States
- Employees
- BYRN N/A
- RLAY N/A
- Industry
- BYRN Industrial Machinery/Components
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYRN Miscellaneous
- RLAY Health Care
- Exchange
- BYRN Nasdaq
- RLAY Nasdaq
- Market Cap
- BYRN 670.5M
- RLAY 610.3M
- IPO Year
- BYRN N/A
- RLAY 2020
- Fundamental
- Price
- BYRN $23.65
- RLAY $3.74
- Analyst Decision
- BYRN Strong Buy
- RLAY Strong Buy
- Analyst Count
- BYRN 2
- RLAY 11
- Target Price
- BYRN $41.50
- RLAY $18.40
- AVG Volume (30 Days)
- BYRN 938.6K
- RLAY 2.4M
- Earning Date
- BYRN 07-10-2025
- RLAY 08-05-2025
- Dividend Yield
- BYRN N/A
- RLAY N/A
- EPS Growth
- BYRN N/A
- RLAY N/A
- EPS
- BYRN 0.62
- RLAY N/A
- Revenue
- BYRN $103,528,000.00
- RLAY $7,679,000.00
- Revenue This Year
- BYRN $37.49
- RLAY $17.59
- Revenue Next Year
- BYRN $21.56
- RLAY N/A
- P/E Ratio
- BYRN $37.98
- RLAY N/A
- Revenue Growth
- BYRN 73.56
- RLAY N/A
- 52 Week Low
- BYRN $7.79
- RLAY $1.78
- 52 Week High
- BYRN $34.78
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- BYRN 41.25
- RLAY 58.29
- Support Level
- BYRN $20.22
- RLAY $3.47
- Resistance Level
- BYRN $24.29
- RLAY $3.97
- Average True Range (ATR)
- BYRN 2.11
- RLAY 0.20
- MACD
- BYRN -0.33
- RLAY -0.00
- Stochastic Oscillator
- BYRN 24.36
- RLAY 54.00
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).